期刊文献+

小儿手足口病中药新药临床试验设计与评价技术指南 被引量:18

Guideline on evaluation of Chinese medical research for treatment of hand-foot-andmouth disease in children
原文传递
导出
摘要 《儿科常见疾病中药新药临床试验设计与评价技术指南》是中华中医药学会儿科分会临床评价学组制定的、指导儿科中药Ⅱ期、Ⅲ期临床试验和上市后有效性再评价方案设计的、具有病种特色的系列临床评价技术指南,旨在推动儿科中药临床试验设计与评价水平的提高,并为临床提供安全有效的儿童用药。采用世界卫生组织(WHO)推荐的"共识会议法"和美国国立卫生研究院(NIH)发展共识方案(GPP)有关原则,国内全部18个国家药物临床试验机构中医儿科专业的临床儿科专家以及国内相关临床评价专家参加了急性上呼吸道感染、急性支气管炎、支气管哮喘、反复呼吸道感染、厌食、轮状病毒性肠炎、注意缺陷–多动障碍、抽动障碍、遗尿症、手足口病、湿疹11个儿科常见病种指南的起草或多次提出修改建议,历经3年反复完善,最终形成共识,并由中华中医药学会儿科分会于2013年10月发布。本指南从研究背景、研究目标、总体设计、诊断标准、受试者的选择、给药方案、安全性评价、有效性评价、试验流程、数据管理与统计分析、质量保证、相关伦理学要求、试验结束后的医疗措施、资料保存等方面阐述了小儿手足口病中药新药临床试验的设计与评价技术要点,期望能为申办者与研究者在临床试验方案设计中提供指导。 The series of Guideline on evaluation of Chinese medical research for treatment of common disease in children were issued by Clinical Evaluation Unit, Pediatric Branch of China Association for Traditional Chinese Medicine. It is developed to assist applicants during the development and re-evaluation of pediatric medicine, in order to provide safer and better medicines for children. The guidelines were developed by all 18 clinical trial institutions of traditional Chinese medicine(TCM), utilized the 'consensus meeting method', which was recommended by WHO, and the consensus development program(GPP) principles of National Institutes of Health(NIH). It involved phases Ⅱ and Ⅲ to post marketing re-evaluation in 11 kinds of pediatric diseases, such as acute upper respiratory infection, acute bronchitis, bronchial asthma, recurrent respiratory tract infections(RRTI), anorexia, rotavirus gastroenteritis, attention-deficit/hyperactivity disorder, tic disorders, enuresis, hand-foot-and-mouth disease, and eczema. It spent three years form the first draft to the last version, after repeated revise, it was eventually released by CACM in October 2013. This Rotavirus Gastroenteritis Guideline intends to address the position in the main topics of clinical development of new Chinese medicinal products in the treatment of rotavirus gastroenteritis in children. The elaboration included possible claims, clinical study design, patients' selection, endpoints, safety observation, as well as other significant points. It aims at providing the possible guidance for sponsor and investigators of clinical trial.
出处 《药物评价研究》 CAS 2015年第5期465-471,共7页 Drug Evaluation Research
基金 国家重大新药创制项目--"儿科中药新药临床评价研究技术平台规范化建设"(2011ZX09302-006-03)
关键词 中药新药 小儿手足口病 临床评价 技术指南 traditional Chinese medicine new drugs rotavirus gastroenteritis in children clinical evaluation guideline
  • 相关文献

参考文献5

二级参考文献75

  • 1奥野良信,万献尧,毕丽岩.金刚烷胺[J].日本医学介绍,2004,25(7):307-309. 被引量:20
  • 2李家泰.临床毒理学与药物评价[J].中国临床药理学杂志,1994,10(3):184-188. 被引量:37
  • 3李密,荆欣,刘彦红,卢宜,王者风,金群英,苏曼昭,谈善华,李美英,谢玉芳,郁天立,李风珍,蔡志基.氨酚待因片Ⅲ期临床监测[J].中国临床药理学杂志,1989,5(4):203-210. 被引量:2
  • 4SCHMIDT N J, LENNETTE E H, HO H H. An apparently new enterovims isolated from patients with disease of the central nervous system[J]. J Infect Dis,1974, 129(3) :304 -309.
  • 5顾岑.急性上呼吸道感染[M]//胡亚美,江载芳.诸福棠实用儿科学.7版.北京:人民卫生出版社,2002:1167-1170.
  • 6陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 7Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol,2008,49 : 103-112.
  • 8Cho HK, Lee NY, Lee H. Enterovirus 71-associated hand, foot and mouth diseases with neurologic symptoms, a university hospital experience in Korea, 2009. Korean J Pediatr,2010,53:639-643.
  • 9Koroleva GA, Lukashev AN, Khudiakova LV. Encephalomyelitis caused by enterovirus type 71 in children. Vopr Virusol,2010,55 : 4-10.
  • 10Chang LY, Lee CY, Kao CL. Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1950-1951 . J Formos Med Assoc,2007,106 : 173-176.

共引文献636

同被引文献208

引证文献18

二级引证文献141

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部